BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp, a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid ...

Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...

(RTTNews) - Labcorp (LH) Wednesday has introduced the pTau-217/Beta Amyloid 42 Ratio test, a blood-based biomarker designed to aid in Alzheimer's diagnosis. Offering accuracy comparable to PET imaging ...

The Elecsys pTau-181 test can help clinicians rule out Alzheimer's disease by identifying patients unlikely to have amyloid pathology — an abnormal protein buildup in the brain associated with the ...

Labcorp Holdings said it would soon offer a blood test for diagnosing Alzheimer's disease in primary-care settings. The Burlington, N.C., lab-services company on Thursday said the Elecsys pTau181 test ...

A new Labcorp technique for early detection of Alzheimer’s disease for adults ages 50 and older has become available nationwide, the Burlington company announced last week.

BURLINGTON, N.C., Feb. 11, 2026 /PRNewswire/ -- Labcorp (LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® pTau-181 ...

Labcorp, one of the country’s largest providers of diagnostic medical testing services, announced today that it will offer the only blood test cleared by the U.S. Food and Drug Administration to aid ...

Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive ...